Arrhythmias & electrophysiology
P-wave terminal force in lead V1 and outcomes in patients with persistent atrial fibrillation undergoing catheter ablation
Authors' conclusion
The PTFV1 at 3 months after AF ablation could be a valuable noninvasive predictor of both AF recurrence and cardiovascular events in patients with persistent AF.
Study context
- Population
- Patients with persistent atrial fibrillation (AF) undergoing first-time AF ablation453 examined
- Participants
- 434 patients
- Exposure
- Abnormal vs normal PTFV1 at 3 months after AF ablation
- Abnormal PTFn = 101
- Normal PTFn = 333reference
- Outcome
- AF recurrence and composite CV events (stroke, HF hospitalization, CV death)
- Follow-up
- 3 years
Methodological detailsconsecutive patients
- Consecutive patients
Main finding
As reported in the abstract
Abnormal PTF
- AF recurrence
- 52.6%
- CV events
- 13.7%
Normal PTF
- AF recurrence
- 28.1%
- CV events
- 2.6%
AF recurrence
Abnormal PTF52.6%
Normal PTF28.1%
CV events
Abnormal PTF13.7%
Normal PTF2.6%
Abnormal PTF vs Normal PTFHazard ratio (95% CI)P value
AF recurrence, adjusted; log-rank P < .001
2.12(1.44–3.13)
P < 0.001CV events, adjusted; log-rank P = .005
3.26(1.19–8.97)
P = 0.022Observational data: associations, not effects.
Original publication
P-wave terminal force in lead V1 and outcomes in patients with persistent atrial fibrillation undergoing catheter ablation. Am Heart J. Published 18 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →